| Species |
Human |
| Protein Construction |
| His |
ENPP-3 (Leu48-Ile875)
Accession # O14638 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
96.15 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 100-130 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 50mM Tris, 150mM NaCl (pH 8.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Ectonucleotide pyrophosphatase-phosphodiesterase 3 (ENPP3), a protein detected in the human uterus, has been found to play an important role in the development and invasion of tumours. It was recently discovered that ENPP3 was upregulated during the window of implantation in the human endometrium but its functional relevance remains elusive. |
| Synonyms |
E-NPP 3; NPP3; PD-Ibeta; NPPase; ENPP3; PDNP3; CD203c; B10; gp130RB13-6; PD-Iβ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
